サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：マイクロバイオーム治療薬の市場規模、市場シェア、アプリケーション分析、地域展望、成長動向、主要企業、競合戦略、予測、2023年～2031年
市場調査レポート
商品コード
1283954

マイクロバイオーム治療薬の市場規模、市場シェア、アプリケーション分析、地域展望、成長動向、主要企業、競合戦略、予測、2023年～2031年

Microbiome Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 To 2031
出版日: | 発行: Acute Market Reports | ページ情報: 英文 117 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
マイクロバイオーム治療薬の市場規模、市場シェア、アプリケーション分析、地域展望、成長動向、主要企業、競合戦略、予測、2023年～2031年
出版日: 2023年05月10日
発行: Acute Market Reports
ページ情報: 英文 117 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

マイクロバイオーム治療薬の市場は、2031年までに32％の成長が見込まれます。マイクロバイオーム治療薬の市場は、今日の世界において豊富な機会を持つ新興市場です。予測期間中、臨床試験に参加している製品の数は、マイクロバイオーム治療薬のに焦点を当てた研究開発活動が世界中で行われていることを証明していると、市場の専門家は指摘しています。マイクロバイオーム市場の構造を考慮すると、その可能性は非常に大きいです。この市場の成長を支える主な要因は、高齢者人口の増加、生活習慣病の増加、高効率で副作用の少ない治療法に対する需要の増加などです。一方、市場の成長を抑制する主な要因としては、市場開拓のための広範な調査不足、プレバイオティクスとプロバイオティクスの効率的な使用と効果に関する国民の意識の低さ、プロバイオティクスとプレバイオティクスに関する政府の規制の差し迫りなどが挙げられます。マイクロバイオーム市場のセグメンテーションは、薬剤の種類、疾患、地域で構成されています。

市場の専門家によると、人体の微生物環境は2010年以降、6億5,000万米ドル以上を集めています。近年、プロバイオティクス、すなわち有益な腸内細菌療法が人気を博しています。これらの製品は、人間のマイクロバイオームを自然な状態に戻すことで、多くの病気を予防する能力を備えています。しかし、マイクロバイオーム治療薬の市場全体はまだ発展途上であるため、投薬の代替や病気の根絶のための治療法として使用することはできません。マイクロバイオーム治療薬の地域別の市場規模は、欧州がトップで、北米がそれに続くと見られています。欧州のマイクロバイオーム治療薬の市場を支えている主な要因は、プロバイオティクスおよびプレバイオティクス製品の高い受容性と認知度の上昇にあるようです。アジア太平洋は、予測期間中、人口と疾病の有病率の点で最も潜在的な地域であることが確認されています。

目次

第1章 序文

  • レポート内容
    • 報告書の目的
    • 対象読者
    • 主な提供商品
  • 市場セグメンテーション
  • 調査手法
    • フェーズⅠ-二次調査
    • フェーズⅡ-一次調査
    • フェーズⅢ-有識者別レビュー
    • 前提条件
    • 採用したアプローチ

第2章 エグゼクティブサマリー

  • 市場スナップショット：世界のマイクロバイオーム治療薬の市場
  • タイプ別の世界のマイクロバイオーム治療薬の市場 2022
  • 用途別の世界のマイクロバイオーム治療薬の市場 2022
  • 地域別の世界のマイクロバイオーム治療薬の市場 2022
  • 魅力的な投資提案：地域別 2022

第3章 マイクロバイオーム治療薬市場：競合分析

  • 主要ベンダーの市場での位置付け
  • ベンダーが採用する戦略
  • 主要な産業戦略
  • ティア分析：2022 vs 2031

第4章 マイクロバイオーム治療薬市場：マクロ分析と市場力学

  • イントロダクション
  • 世界のマイクロバイオーム治療薬の市場価値 2021-2031
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析

第5章 マイクロバイオーム治療薬市場、タイプ別： 2021-2031

  • 市場概要
  • 成長・収益分析：2022 vs 2031
  • 市場セグメンテーション
    • FMT
    • マイクロバイオーム薬

第6章 マイクロバイオーム治療薬市場、用途別： 2021-2031

  • 市場概要
  • 成長・収益分析：2022 vs 2031
  • 市場セグメンテーション
    • C.ディフィシル
    • クローン病
    • 炎症性腸疾患
    • 糖尿病
    • その他

第7章 北米のマイクロバイオーム治療薬市場： 2021-2031

  • 市場概要
  • マイクロバイオーム治療薬市場、タイプ別： 2021-2031
  • マイクロバイオーム治療薬市場、用途別： 2021-2031
  • マイクロバイオーム治療薬市場、地域別： 2021-2031
    • 北米
      • 米国
      • カナダ
      • その他北米地域

第8章 英国および欧州連合のマイクロバイオーム治療薬市場： 2021-2031

  • 市場概要
  • マイクロバイオーム治療薬市場、タイプ別： 2021-2031
  • マイクロバイオーム治療薬市場、用途別： 2021-2031
  • マイクロバイオーム治療薬市場、地域別： 2021-2031
    • 英国と欧州連合
      • 英国
      • ドイツ
      • スペイン
      • イタリア
      • フランス
      • その他欧州地域

第9章 アジア太平洋のマイクロバイオーム治療薬市場： 2021-2031

  • 市場概要
  • マイクロバイオーム治療薬市場、タイプ別： 2021-2031
  • マイクロバイオーム治療薬市場、用途別： 2021-2031
  • マイクロバイオーム治療薬市場、地域別： 2021-2031
    • アジア太平洋
      • 中国
      • 日本
      • インド
      • オーストラリア
      • 韓国
      • その他アジア太平洋地域

第10章 ラテンアメリカのマイクロバイオーム治療薬市場： 2021-2031

  • 市場概要
  • マイクロバイオーム治療薬市場、タイプ別： 2021-2031
  • マイクロバイオーム治療薬市場、用途別： 2021-2031
  • マイクロバイオーム治療薬市場、地域別： 2021-2031
    • ラテンアメリカ
      • ブラジル
      • メキシコ
      • その他ラテンアメリカ地域

第11章 中東およびアフリカのマイクロバイオーム治療薬市場： 2021-2031

  • 市場概要
  • マイクロバイオーム治療薬市場、タイプ別： 2021-2031
  • マイクロバイオーム治療薬市場、用途別： 2021-2031
  • マイクロバイオーム治療薬市場、地域別： 2021-2031
    • 中東・アフリカ
      • GCC
      • アフリカ
      • その他中東・アフリカ地域

第12章 企業プロファイル

  • OpenBiome
  • Seres Therapeutics Inc.
  • 4D Pharma plc.
  • Locus Biosciences Inc.
  • Enterome SA
  • Finch Therapeutics Group Inc.
  • Intralytix Inc.
  • Microbiotica
  • Second Genome
  • Rebiotix Inc.
  • Vedanta Bioscience Inc.
  • その他の注目企業
図表

List of Tables

  • TABLE 1 Global Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 2 Global Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 3 North America Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 4 North America Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 5 U.S. Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 6 U.S. Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 7 Canada Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 8 Canada Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 9 Rest of North America Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 10 Rest of North America Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 11 UK and European Union Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 12 UK and European Union Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 13 UK Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 14 UK Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 15 Germany Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 16 Germany Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 17 Spain Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 18 Spain Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 19 Italy Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 20 Italy Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 21 France Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 22 France Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 23 Rest of Europe Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 24 Rest of Europe Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 25 Asia Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 26 Asia Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 27 China Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 28 China Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 29 Japan Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 30 Japan Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 31 India Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 32 India Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 33 Australia Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 34 Australia Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 35 South Korea Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 36 South Korea Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 37 Latin America Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 38 Latin America Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 39 Brazil Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 40 Brazil Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 41 Mexico Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 42 Mexico Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 43 Rest of Latin America Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 44 Rest of Latin America Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 45 Middle East and Africa Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 46 Middle East and Africa Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 47 GCC Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 48 GCC Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 49 Africa Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 50 Africa Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)
  • TABLE 51 Rest of Middle East and Africa Microbiome Therapeutics Market By Type, 2021-2031, USD (Million)
  • TABLE 52 Rest of Middle East and Africa Microbiome Therapeutics Market By Application, 2021-2031, USD (Million)

List of Figures

  • FIG. 1 Global Microbiome Therapeutics Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Microbiome Therapeutics Market: Quality Assurance
  • FIG. 5 Global Microbiome Therapeutics Market, By Type, 2022
  • FIG. 6 Global Microbiome Therapeutics Market, By Application, 2022
  • FIG. 7 Global Microbiome Therapeutics Market, By Geography, 2022
  • FIG. 8 Market Geographical Opportunity Matrix - Global Microbiome Therapeutics Market, 2022
  • FIG. 9 Market Positioning of Key Microbiome Therapeutics Market Players, 2022
  • FIG. 10 Global Microbiome Therapeutics Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031
  • FIG. 11 Global Microbiome Therapeutics Market, By Type, 2022 Vs 2031, %
  • FIG. 12 Global Microbiome Therapeutics Market, By Application, 2022 Vs 2031, %
  • FIG. 13 U.S. Microbiome Therapeutics Market (US$ Million), 2021 - 2031
  • FIG. 14 Canada Microbiome Therapeutics Market (US$ Million), 2021 - 2031
  • FIG. 15 Rest of North America Microbiome Therapeutics Market (US$ Million), 2021 - 2031
  • FIG. 16 UK Microbiome Therapeutics Market (US$ Million), 2021 - 2031
  • FIG. 17 Germany Microbiome Therapeutics Market (US$ Million), 2021 - 2031
  • FIG. 18 Spain Microbiome Therapeutics Market (US$ Million), 2021 - 2031
  • FIG. 19 Italy Microbiome Therapeutics Market (US$ Million), 2021 - 2031
  • FIG. 20 France Microbiome Therapeutics Market (US$ Million), 2021 - 2031
  • FIG. 21 Rest of Europe Microbiome Therapeutics Market (US$ Million), 2021 - 2031
  • FIG. 22 China Microbiome Therapeutics Market (US$ Million), 2021 - 2031
  • FIG. 23 Japan Microbiome Therapeutics Market (US$ Million), 2021 - 2031
  • FIG. 24 India Microbiome Therapeutics Market (US$ Million), 2021 - 2031
  • FIG. 25 Australia Microbiome Therapeutics Market (US$ Million), 2021 - 2031
  • FIG. 26 South Korea Microbiome Therapeutics Market (US$ Million), 2021 - 2031
  • FIG. 27 Rest of Asia Microbiome Therapeutics Market (US$ Million), 2021 - 2031
  • FIG. 28 Brazil Microbiome Therapeutics Market (US$ Million), 2021 - 2031
  • FIG. 29 Mexico Microbiome Therapeutics Market (US$ Million), 2021 - 2031
  • FIG. 30 Rest of Latin America Microbiome Therapeutics Market (US$ Million), 2021 - 2031
  • FIG. 31 GCC Microbiome Therapeutics Market (US$ Million), 2021 - 2031
  • FIG. 32 Africa Microbiome Therapeutics Market (US$ Million), 2021 - 2031
  • FIG. 33 Rest of Middle East and Africa Microbiome Therapeutics Market (US$ Million), 2021 - 2031
目次
Product Code: 136931-05-23

Microbiome Therapeutics Market is Expected to Grow at 32% by 2031. Microbiome therapeutics market is an emerging market with abundant opportunities in today's world. During the forecast period market experts suggest that number of products currently involved in clinical trials proves the amount of research and development activities carried out across the world focusing on microbiome therapeutics. Considering the structure of the microbiome market the potential is quite large. The key factors assisting the growth of this market comprise rising geriatric population, increasing incidences of lifestyle diseases, increasing demand for treatments with high efficiency and low side effects. The major factors that are expected to restrain the growth of this market are lack of broad research to aid the market pull, low awareness among the population related to the efficient usage and effect of prebiotics and probiotics, and impending government regulations on probiotics and prebiotics. The segmentation of microbiome market comprises of type of drugs, diseases, and geography.

Market experts suggest that the microbial landscape of human body has attracted more than US$ 650 Mn since 2010. In recent years, probiotics, or beneficial gut bacteria therapy, have been popular. These products possess capacity of preventing number of diseases by restoring the human microbiome to its natural state. However, the overall microbiome therapeutics market is still in its infancy; hence, cannot be used as a replacement for medication or as a treatment for the eradication of the disease. Europe was observed as the leading regional market for microbiome therapeutics followed by North America. The key factors assisting the microbiome therapeutics market in Europe are due to high acceptance and rising awareness of probiotic and prebiotic products. Asia-Pacific was observed as the most potential region in terms of population and prevalence of disease throughout the forecast period.

Key Players Identified for Microbiome Therapeutics Market Include but are Not Limited to:

OpenBiome, Seres Therapeutics Inc., 4D Pharma plc., Locus Biosciences, Inc., Enterome SA, Finch Therapeutics Group, Inc., Intralytix, Inc., Microbiotica, Second Genome, Rebiotix Inc., Vedanta Bioscience, Inc. And Other Notable Players.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Microbiome Therapeutics market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Microbiome Therapeutics market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Type

  • FMT
  • Microbiome Drugs

Application

  • C. difficile
  • Crohn's disease
  • Inflammatory Bowel Disease
  • Diabetes
  • Others

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Microbiome Therapeutics market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Microbiome Therapeutics market?
  • Which is the largest regional market for Microbiome Therapeutics market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Microbiome Therapeutics market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Microbiome Therapeutics market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Microbiome Therapeutics Market
  • 2.2. Global Microbiome Therapeutics Market, By Type, 2022 (US$ Million)
  • 2.3. Global Microbiome Therapeutics Market, By Application, 2022 (US$ Million)
  • 2.4. Global Microbiome Therapeutics Market, By Geography, 2022 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2022

3. Microbiome Therapeutics Market: Competitive Analysis

  • 3.1. Market Positioning of Key Microbiome Therapeutics Market Vendors
  • 3.2. Strategies Adopted by Microbiome Therapeutics Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Microbiome Therapeutics Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Microbiome Therapeutics Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. FMT
    • 5.3.2. Microbiome Drugs

6. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. C. difficile
    • 6.3.2. Crohn's disease
    • 6.3.3. Inflammatory Bowel Disease
    • 6.3.4. Diabetes
    • 6.3.5. Others

7. North America Microbiome Therapeutics Market, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
  • 7.3. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
  • 7.4.Microbiome Therapeutics Market: By Region, 2021-2031, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 7.4.1.1.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 7.4.1.2.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 7.4.1.3.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)

8. UK and European Union Microbiome Therapeutics Market, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
  • 8.3. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
  • 8.4.Microbiome Therapeutics Market: By Region, 2021-2031, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 8.4.1.1.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 8.4.1.2.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 8.4.1.3.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 8.4.1.4.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 8.4.1.5.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 8.4.1.6.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)

9. Asia Pacific Microbiome Therapeutics Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
  • 9.3. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
  • 9.4.Microbiome Therapeutics Market: By Region, 2021-2031, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 9.4.1.1.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 9.4.1.2.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 9.4.1.3.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 9.4.1.4.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 9.4.1.5.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 9.4.1.6.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)

10. Latin America Microbiome Therapeutics Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
  • 10.3. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
  • 10.4.Microbiome Therapeutics Market: By Region, 2021-2031, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 10.4.1.1.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 10.4.1.2.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 10.4.1.3.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)

11. Middle East and Africa Microbiome Therapeutics Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
  • 11.3. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
  • 11.4.Microbiome Therapeutics Market: By Region, 2021-2031, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 11.4.1.1.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 11.4.1.2.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
        • 11.4.1.3.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)

12. Company Profile

  • 12.1. OpenBiome
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Seres Therapeutics Inc.
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. 4D Pharma plc.
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Locus Biosciences, Inc.
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Enterome SA
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Finch Therapeutics Group, Inc.
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. Intralytix, Inc.
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Microbiotica
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Second Genome
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Rebiotix Inc.
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives
  • 12.11. Vedanta Bioscience, Inc.
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Product Portfolio
    • 12.11.4. Strategic Initiatives
  • 12.12. Other Notable Players
    • 12.12.1. Company Overview
    • 12.12.2. Financial Performance
    • 12.12.3. Product Portfolio
    • 12.12.4. Strategic Initiatives